About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Features and Outcomes of Patients With Reactive Arthritis

Clinicaltrials.gov identifier NCT03926429

Recruitment Status Completed

First Posted April 24, 2019

Last update posted April 24, 2019

Study Description

Brief summary:

The aim of this study is to assess the incidence and the clinical and therapeutic characteristics of reactive arthritis and to compare them with those of a historical cohort. We hypothesised that improved hygiene together with prevention and treatment of sexually transmitted infections may have decreased the incidence of reactive arthritis.

  • Condition or Disease:Arthritis
  • Intervention/Treatment: Other: Standardised data collection
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Observational
  • Actual Enrollment: 58 participants
  • Observational Model: Cohort
  • Time Perspective: Retrospective
  • Official Title: A Bicentre Retrospective Study of Features and Outcomes of Patients With Reactive Arthritis
  • Actual Study Start Date: February 2013
  • Actual Primary Completion Date: December 2014
  • Actual Study Completion Date: December 2014
Groups and Cohorts
Groups/Cohorts Intervention/treatment
: Patient with reactive arthritis
Other: Standardised data collection
The following variables will be retrospectively assessed by medical record review using a standardised data collection form:demographics; gender, age; family or personal history of spondyloarthritis, psoriasis, uveitis, inflammatory bowel disease; clinical presentation; mono, oligo or polyarthritis, dactylitis, inflammatory joint pain, enthesopathy, axial symptoms, fever, extra-articular manifestations (conjunctivitis, anterior uveitis, circinate balanitis, skin rash); time interval between infection and musculoskeletal manifestations; causal microorganism if known, or triggering event; HLA-B27; radiographic sacroiliitis; treatments and outcomes (complete recovery at one year follow-up, relapse within 6 months after onset, or spondyloarthritis according to the ASAS criteria).
Outcome Measures
  • Primary Outcome Measures: 1. To determine the incidence of reactive arthritis in patients hospitalised in the rheumatology department [ Time Frame: December 2014 ]
    Incidence of reactive arthritis in patients hospitalised in the rheumatology department
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: Patients with active reactive arthritis
Criteria

Inclusion Criteria:

- reactive arthritis diagnosed in one of the two rheumatology departments from Centre
Hospitalier Lyon Sud or Besançon

Exclusion Criteria:

- presence of other known causes of arthritis, such as other defined
spondyloarthritides, septic arthritis, Lyme disease, microcrystalline arthritis or
rheumatoid arthritis

Contacts and Locations
Contacts
Locations

France
CHU de Besançon
Besançon

France
Centre Hospitalier Lyon Sud
Pierre-Bénite

Sponsors and Collaborators

Hospices Civils de Lyon

Investigators

Principal Investigator: Fabienne COURY-LUCAS, MD Hospices Civils de Lyon

More Information
  • Responsible Party: Hospices Civils de Lyon
  • ClinicalTrials.gov Identifier: NCT03926429 History of Changes
  • Other Study ID Numbers: FOPRA
  • First Posted: April 24, 2019 Key Record Dates
  • Last Update Posted: April 24, 2019
  • Last Verified: April 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Arthritis Arthritis, Reactive